期刊文献+

细菌耐药的外排机制及其抑制剂 被引量:17

The Efflux Mechanism of Bacterial Drug Resistance and Inhibitors
下载PDF
导出
摘要 细菌对药物产生耐药性的机制多种多样,主动外排(efflux)是重要和常见的耐药机制之一.主动外排过程是细菌不同种类的外排蛋白系统将药物从自身体内主动外泵排出的过程.主动外排耐药机制属于非特异性耐药机制,具有底物广、能量依赖、外排泵种类多和外排泵来源菌多的特点.外排泵广泛存在于革兰阳性菌、革兰阴性菌和分枝杆菌中,因此抑制耐药细菌的一条重要途径是寻找和发现外排泵抑制剂.外排泵抑制剂通过抑制外排泵对抗生素药物的外排作用,从而恢复细菌对抗生素的敏感性.外排泵抑制剂可根据所作用的外排泵能量来源不同分为ATP水解能驱动型外排泵抑制剂和跨膜质子梯度能驱动型外排泵抑制剂两大类;也可依据所抑制的外排泵蛋白种类不同分为NorA蛋白抑制剂,Mex外排泵抑制剂,Tet(B)外排泵抑制剂,以及AcrAB-TolC外排泵抑制剂等多种类型.各种类型的外排泵抑制剂将成为解决细菌耐药问题的有效方法之一. The mechanisms of bacterial drug resistance were various. One of the most important and common mechanisms is active efflux system of bacteria. During the process of efflux, different kinds of efflux protein could discharge drugs initiatively. The active efflux belongs to nonspecific resistant mechanism, with the features of substrate universality, energy dependence, species and source diversity. Efflux pumps are widely found in Gram-positive bacteria, Gram-negative bacteria and Mycobacteria . Finding efflux pump inhibitors is an important way to inhibit drug-resistant bacteria because they could restore bacterial sensitivity to antibiotics by inhibiting the efflux effects of bacteria. The efflux pump inhibitors can be divided into two categories according to their energy sources: ATP hydrolytic energy driven efflux pump inhibitors and transmembrane proton gradient energy driven efflux pump inhibitors. They can also be classified as NorA protein inhibitors, Mex, Tet(B), AcrAB-TolC, et al efflux pump inhibitors according to the type of the efflux pump protein inhibited. Various types of efflux pump inhibitors will be one of the effective methods to overcome bacterial drug resistance.
作者 孙仲琳 崔锦 王锐 穆青 SUN Zhonglin;CUI Jin;WANG Rui;MU Qing(School of Pharmacy, Fudan University, Shanghai 201203, China;Zhaotong College, Zhaotong Yunnan 657000, China)
出处 《复旦学报(自然科学版)》 CAS CSCD 北大核心 2019年第2期135-143,共9页 Journal of Fudan University:Natural Science
关键词 细菌耐药性 外排泵 外排泵抑制剂 bacterial drug resistance efflux pumps efflux pump inhibitors
  • 相关文献

参考文献3

二级参考文献28

  • 1Varma MVS,Ashokraj Y,Dey CS,et al.P-glycoprotein inhibitors and their screening:a perspective from bioavailability enhancement[J].Pharm Res,2003,48(4):347-359. 被引量:1
  • 2Jeremy PB,Katherine AV,Susan H,et al.Evaluation of toremifen for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine[J].Cancer Chemother Pharmacol,2000,46(1):27-34. 被引量:1
  • 3Teodori E,Dei S,Quidu P,et al.Design,synthesis,and in vitro activity of catamphiphilic reversers of multidrug resistance:discovery of a selective,highly efficacious chemosensitizer with potency in the nanomolar range[J].J Med Chem,1999,42(10):1687-1697. 被引量:1
  • 4Loe DW,Oleschuk CJ,Deeley RG,et al.Structure-activity studies of verapamil analogs that modulate transport of leukotriene C4 and reduced glutathione by multidrug resistance protein MRP1[J].Biochem Biophy Res Commun,2000,275(3):795-803. 被引量:1
  • 5Advani R,Saba HI,Tallman MS,et al.Treatment of refractory and relapsed acute myelogeous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833(valspodar)[J].Blood,1999,93(3):787-795. 被引量:1
  • 6Seiden MV,Swenerton KD,Matulonis U,et al.A phase Ⅱ study of the MDR inhibitor biricodar(incel,VX-710)and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy[J].Gynecol Oncol,2002,86(3):302-310. 被引量:1
  • 7Nokihara H,Yano S,Nishioka Y,et al.A new quinoline derivative MS-209 resistance and inhibits multiorgen metastases by P-glycoprotain-expressing human small cell lung cancer cells[J].Cancer Res,2001,92(7):785-792. 被引量:1
  • 8Planting AS,Sonneveld P,van der Gaast A,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99. 被引量:1
  • 9Gallo S,Atifi S,Mahamoud A,et al.Synthesis of aza mono,bi- and tricyclic compounds.Evaluation of their anti MDR activity[J].Eur J Med Chem,2003,38(1):19-26. 被引量:1
  • 10Sandler A,Gordon M,de Alwis DP,et al.A phaseⅠtrial of a potent P-glycoprotein inhibitor,zosuquidar trihydrochloride(LY335979),administered intravenously in combination with doxorubicin in patients with advanced malignancy[J].Clin Cancer Res,2004,10(10):3265-3272. 被引量:1

共引文献48

同被引文献210

引证文献17

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部